Research was conducted for the investment bank underwriting the IPO of a healthcare company. Research identified a recent short-stint chairmanship at an investment fund not disclosed by one of the proposed independent directors. Further research showed that the fund was one of a number of vehicles used by a serial fraudster banned from serving as a director in a number of jurisdictions. After the director was asked to explain his association with the fund and the fraudster, additional research was conducted which demonstrated that the director was not completely forthcoming with his explanation and was subsequently removed from the proposed role.
CRA recognized in Chambers 2026 for litigation support and crisis & risk management
Charles River Associates has been recognized in the 2026 Chambers Litigation Support and Crisis & Risk Management Guides, including a Band 1 global ranking...